Stereotactic body radiotherapy for treatment of liver metastasis

В данной работе было изучено методологию планирования VMAT. Роль предварительной обработки топометрии, планирования лечения, планов контроля качества, и доставки лечения пяти пациентам с метастазами в печени в Томском Областном Онкологическом Центре.In this work was study the planning methodology of VMAT. the role of pre-treatment topometry, treatment planning, quality control plans, and delivery of treatment to five patients with liver metastases in the Tomsk Regional Oncology Center

Stereotactic body radiotherapy for treatment of liver metastasis

В данной работе было изучено методологию планирования VMAT. Роль предварительной обработки топометрии, планирования лечения, планов контроля качества, и доставки лечения пяти пациентам с метастазами в печени в Томском Областном Онкологическом Центре.In this work was study the planning methodology of VMAT. the role of pre-treatment topometry, treatment planning, quality control plans, and delivery of treatment to five patients with liver metastases in the Tomsk Regional Oncology Center

Vandetanib-eluting radiopaque beads and stereotactic body radiotherapy in the treatment of liver cancers

Background: Current treatment options for unresectable hepatocellular carcinoma (HCC) and colorectal liver metastases (mCRC) include transarterial chemoembolisation (TACE) and stereotactic body radiotherapy (SBRT). The objectives of this project were: 1. To assess a novel drug-eluting bead for TACE / 2. To report on the safety and efficacy of SBRT in HCC / 3. To assess the feasibility of using radiopaque beads as fiducial markers for SBRT / Methods: In Part 1, a first-in-human trial was performed in patients with HCC and mCRC using a novel vandetanib-eluting radiopaque bead, BTG-002814. Primary trial endpoints were safety/tolerability and the concentrations of vandetanib and its major metabolite in plasma and resected tissue. Biomarker studies included blood cytokines and perfusion imaging parameters. In Part 2, the efficacy of SBRT was explored in a retrospective study of 31 patients with HCC tumours ≤5 cm and in a phase II study of 13 patients with larger tumours. In Part 3 the feasibility of using radiopaque beads as fiducial markers for SBRT was investigated. / Results: BTG-002814 was shown to have a satisfactory safety profile in 8 patients. Vandetanib was present in the plasma of all patients 12 days post-TACE, and present in resected liver tissue up to 32 days post-treatment. There were no significant changes in perfusion parameters. Blood biomarker studies showed increases in leptin, osteopontin and sTie2. SBRT offered 1-year local control rates of 94% in small HCCs and 92% in larger tumours. Radiopaque beads were visible on 4D-CT and CBCT images in all 8 cases and matching successfully performed. / Conclusions: The safety profile and pharmacokinetic characteristics for this novel technology are adequate to proceed to a Phase I/II trial. SBRT is an effective local treatment for HCC. The role of radiopaque beads as fiducial markers is feasible and warrants further exploration as a clinical trial of TACE with SBRT